MELBOURNE, Australia and SAN FRANCISCO, April 28, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer presented the ATH434-201 Phase 2 clinical trial results at the annual MSA Research Symposium hosted by University College London, Institute of Neurology in partnership with the MSA Tru ...

- Preclinical presentation highlights key, modality specific, pharmacological differentiations of VG-3927 - - First presentation of topline clinical data from Phase 1 SAD/MAD trial of VG-3927 for the potential treatment of Alzheimer’s disease (AD) - WATERTOWN, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today presented data highlighting ...

NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will present at the 24th Annual Needham Virtual Healthcare Conference, April 7 – 10, 2025. C ...

Core Insights - Vigil Neuroscience announced positive Phase 1 clinical trial data for VG-3927, a potential treatment for Alzheimer's Disease, and plans to initiate a Phase 2 trial in Q3 2025 [1][2] - The company is on track to report final analysis from the IGNITE Phase 2 clinical trial for iluzanebart in ALSP in Q2 2025 [1][2] Recent Developments - Positive Phase 1 data for VG-3927 supports its advancement as a Phase 2-ready oral small molecule TREM2 agonist, potentially offering a new therapy for Alzheimer's disease [2][4] - The IGNITE Phase 2 trial for iluzanebart is expected to provide critical data for a potential breakthrough therapy for ALSP [2][4] Financial Performance - As of December 31, 2024, cash, cash equivalents, and marketable securities totaled $97.8 million, down from $111.3 million as of September 30, 2024 [8][13] - Research and Development (R&D) expenses for Q4 2024 were $18.7 million, compared to $16.8 million in Q4 2023, driven by increased clinical activity [8][11] - General and Administrative (G&A) expenses decreased to $6.4 million in Q4 2024 from $7.1 million in Q4 2023, attributed to lower external professional service fees [8][11] Clinical Trial Details - The Phase 1 trial for VG-3927 included 115 participants, demonstrating a favorable safety profile and a robust dose-dependent reduction of sTREM2 in cerebral spinal fluid [4][8] - The company plans to present Phase 1 data at the AD/PD™ 2025 International Conference on Alzheimer's and Parkinson's Disease in April 2025 [4][8]